Member Rachel Alexander was quoted in a recent Bloomberg Law article about Medicare drug price cuts and what they might mean for ongoing litigation. Rachel addresses the potential implications of the US government’s release Thursday of the first ten drug prices that were negotiated for Medicare.

According to Rachel, the list of prices may provide “a new piece of the puzzle” for certain legal challenges. She says, “Appellants may have new evidence to show tangible harms resulting from low maximum fair prices.”

Source

Bloomberg Law